Risk evaluation of denosumab and zoledronic acid for medication-related osteonecrosis of the jaw in patients with bone metastases: a propensity score–matched analysis

Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL

Hisataka Yasuda, Nobuyuki Shima, N. Nakagawa et al. · Proceedings of the National Academy of Sciences · 1998 · 4.2K citations · Full text

Osteoprotegerin/osteoclastogenesis-inhibitory Factor, Sclerostin, Tumor Microenvironment +14

American Association of Oral and Maxillofacial Surgeons Position Paper on Medication-Related Osteonecrosis of the Jaw—2014 Update

Salvatore L. Ruggiero, Thomas B. Dodson, John E Fantasia et al. · Journal of Oral and Maxillofacial Surgery · 2014 · 2.9K citations

Medication-related Osteonecrosis, Oral Surgery, American Association +9

Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study

Karim Fizazi, Michael A. Carducci, Matthew R. Smith et al. · The Lancet · 2011 · 1.9K citations · Full text

Urology, Surgical Oncology, Medicine +9

Osimertinib in Resected <i>EGFR</i> -Mutated Non–Small-Cell Lung Cancer

Yi‐Long Wu, Masahiro Tsuboi, Jie He et al. · New England Journal of Medicine · 2020 · 1.7K citations · Full text

Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC

Roy S. Herbst, Giuseppe Giaccone, Filippo de Marinis et al. · New England Journal of Medicine · 2020 · 1.6K citations · Full text